/ EN

Online Contract Signing Ceremony: Xi'an Yufan Biotechnology plans to invest 100 million Yuan to build a CAR-T cell manufacturing facility

  • Categories:Industry News
  • Author:
  • Origin:
  • Time of issue:2020-02-22 12:20
  • Views:

Online Contract Signing Ceremony: Xi'an Yufan Biotechnology plans to invest 100 million Yuan to build a CAR-T cell manufacturing facility

  • Categories:Industry News
  • Author:
  • Origin:
  • Time of issue:2020-02-22 12:20
  • Views:
Information

On Feb 22, 2020, a contract signing ceremony of Xi 'an Biomedical Industry Cluster Group was held in Xi 'an High-tech District. To ensure the safety of participants during the pandemic, the contract signing was carried out via a special online ceremony, changing the way of contract signing from "face to face" to "screen to screen".

Thirty biomedical projects were signed in the ceremony, with a total investment of 28.6 billion Yuan, involving chemical drug, traditional Chinese medicine, biological drug, medical device, etc. Among the projects, Xi 'an Yufan Biotechnology Co., LTD. (hereinafter referred to as Xi 'an Yufan Biotechnology) announced a plan of investing 100 million Yuan to build a manufacturing facility to produce CAR-T cells for the treatment of refractory leukemia and lymphoma.

 

 

Hao Wang, a member of the Standing Committee of the Provincial Party and  Secretary of the Municipal Party, Yunguo Wu, Chairman of China Enterprise News Group, Hongfeng Ying, Director of Provincial Food and Drug Administration, Wen Xu, Director of the Provincial Bank Insurance Supervision Bureau, and Riqiang Zhai, Chairman of Shanxi Pharmaceutical Holding Co. Ltd. attended the contract signing ceremony. Hongjiang Zhong, a member of the Standing Committee of Xi 'an Municipal Party, Secretary of the Party Labor Committee of High-tech District,  Secretary of the Party Labor Committee of the Space Base, presided over this meeting. Xiaodong Yang from municipal government, Yong Wang, Deputy Secretary of the Party Labor Committee of High-tech District, and Haibin Qi, Director of the Management Committee of High-tech District also attended the meeting. Prof. Xuebin Liao, the founder of Xi 'an Yufan Biological Co. Ltd., attended this online contract signing ceremony and signed the collaboration agreement on behalf of the company.

As a subsidiary of Guangzhou MingMed Biotechnology Co., Ltd., Xi'an Yufan Biotechnology Co., Ltd. focuses on the CAR-T cell immunotherapy, and set up an immune oncology research center and an antibody screening platform. The company was founded in July 2016 and has completed Round A financing.

Xi'an Yufan Biological Co. Ltd. is founded by scientists with global vision. The senior management team have been trained in the United States for years. The company uses gene editing technology to significantly improve the target killing capability and the infiltration of T cells and prolong T cells survival. In addition, the company has set up a high capacity human antibody phage display platform to select antibodies with high specificity and binding capability for different tumor biomarkers and apply the antibodies to  innovative CAR-T cells preparation. The phage library is also used to screen neutralizing antibody for antiviral and autoimmune therapy.

Driven by the motto of "Lead cancer immunotherapy technology, turn technology into art", the company will make concerted efforts to build a world-class cancer immunotherapy research center in China.

imgboxbg

Home   丨   About Us   丨   Product and Pipeline   丨   Our Team   丨   News   丨   Career   丨   Contact

Address: 106 Fengze East Road, Nansha District, Guangzhou 
Email: ming-med@ming-med.com

Copyright © 2020 ming-med.com  保留所有权利  粤ICP备20029450号-1